Remission more appropriate as a secondary endpoint in RA trials: experts


Remission is an unhelpful outcome measure in clinical trials in early rheumatoid arthritis and the 28 joint-count Disease Activity Score (DAS28) should be relegated to, at best, a secondary endpoint, a European task force has concluded. It was responding to a draft guideline from the European Medicines Agency (EMA) which proposed remission as a primary ...


Already a member? Login to keep reading


OR
© 2017 the limbic